Effect of combined 5-aza-2'deoxycytidine and cisplatin treatment on the P15 lung adenocarcinoma cell line

Liu,Kaishan; Huang,Wenyan; Gao,Weisong; He,Wenfang

doi:10.3892/ol.2015.2986

Effect of combined 5-aza-2'deoxycytidine and cisplatin treatment on the P15 lung adenocarcinoma cell line

Authors:
- Kaishan Liu
- Wenyan Huang
- Weisong Gao
- Wenfang He
View Affiliations

Affiliations: Department of Pathology, School of Medicine, Jinan University, Guangzhou, Guangdong 510632, P.R. China
Published online on: February 26, 2015 https://doi.org/10.3892/ol.2015.2986
Pages: 2007-2012
Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Aberrant promoter hypermethylation resulting in the epigenetic silencing of apoptosis‑associated genes is a key process in the chemotherapeutic treatment of cancer. The nucleoside analog, 5‑aza‑2'deoxycytidine (DAC), inhibits the activity of DNA methyltransferase enzymes and is able to restore the expression levels of genes that have been silenced by aberrant DNA methylation. The aim of the present study was to investigate the effect of combined treatment with DAC and cisplatin (CDDP) on the lung adenocarcinoma cell line, P15. Growth inhibition was examined using a clone formation assay and growth inhibitory activities by cell counting during treatment with DAC alone, CDDP alone or DAC followed by CDDP. In addition, changes in the mRNA expression levels of various apoptosis‑associated genes following treatment with increasing concentrations of DAC were determined using reverse transcription‑polymerase chain reaction. Furthermore, terminal deoxynucleotidyl transferase‑mediated dUTP nick end labeling (TUNEL) analysis was used to detect the number of apoptotic P15 tumor cells following treatment with DAC and/or CDDP. The results indicated that DAC treatment alone restored the mRNA expression levels of p73, p16INK4a, B‑cell lymphoma (Bcl)‑2‑associated agonist of cell death and Bcl‑2‑associated X protein. In addition, combined therapy with DAC and CDDP was found to significantly suppress the growth of P15 tumor cells compared with DAC or CDDP treatment alone. In conclusion, DAC may enhance the chemosensitivity of the P15 cell line to treatment with CDDP.

View Figures

View References

1	Field JK, Oudkerk M, Pedersen JH and Duffy SW: Prospects for population screening and diagnosis of lung cancer. Lancet. 382:732–741. 2013. View Article : Google Scholar : PubMed/NCBI
2	Reck M, Heigener DF, Mok T, Soria JC and Rabe KF: Management of non-small-cell lung cancer: recent developments. Lancet. 382:709–719. 2013. View Article : Google Scholar : PubMed/NCBI
3	Ozawa Y, Inui N, Naitoh T, et al: Phase II study of combination chemotherapy with S-1 and weekly cisplatin in patients with previously untreated advanced non-small cell lung cancer. Lung Cancer. 63:68–71. 2009. View Article : Google Scholar : PubMed/NCBI
4	Barr MP, Gray SG, Hoffmann AC, et al: Generation and characterisation of cisplatin-resistant non-small cell lung cancer cell lines displaying a stem-like signature. PloS One. 8:e541932013. View Article : Google Scholar : PubMed/NCBI
5	Sève P and Dumontet C: Chemoresistance in non-small cell lung cancer. Curr Med Chem Anticancer Agents. 5:73–88. 2005. View Article : Google Scholar : PubMed/NCBI
6	Almeida GM, Duarte TL, Farmer PB, Steward WP and Jones GD: Multiple end-point analysis reveals cisplatin damage tolerance to be a chemoresistance mechanism in a NSCLC model: implications for predictive testing. Int J Cancer. 122:1810–1819. 2008. View Article : Google Scholar : PubMed/NCBI
7	McCabe MT, Brandes JC and Vertino PM: Cancer DNA methylation: molecular mechanisms and clinical implications. Clin Cancer Res. 15:3927–3937. 2009. View Article : Google Scholar : PubMed/NCBI
8	Cheung HH, Lee TL, Rennert OM and Chan WY: DNA methylation of cancer genome. Birth Defects Res C Embryo Today. 87:335–350. 2009. View Article : Google Scholar : PubMed/NCBI
9	Fang JY, Yang L, Zhu HY, Chen YX, Lu J, Lu R, Cheng ZH and Xiao SD: 5-Aza-2′-deoxycitydine induces demethylation and up-regulates transcription of p16INK4a gene in human gastric cancer cell lines. Chin Med J (Engl). 117:99–103. 2004.PubMed/NCBI
10	Chu LC, Eberhart CG, Grossman SA and Herman JG: Epigenetic silencing of multiple genes in primary CNS lymphoma. Int J Cancer. 119:2487–2491. 2006. View Article : Google Scholar : PubMed/NCBI
11	Karahoca M and Momparler RL: Pharmacokinetic and pharmacodynamic analysis of 5-aza-2′-deoxycytidine (decitabine) in the design of its dose-schedule for cancer therapy. Clin Epigenetics. 5:32013. View Article : Google Scholar : PubMed/NCBI
12	Mund C, Hackanson B, Stresemann C, Lübbert M and Lyko F: Characterization of DNA demethylation effects induced by 5-aza-2′-deoxycytidine in patients with myelodysplastic syndrome. Cancer Res. 65:7086–7090. 2005. View Article : Google Scholar : PubMed/NCBI
13	Belinsky SA: Gene-promoter hypermethylation as a biomarker in lung cancer. Nat Rev Cancer. 4:707–717. 2004. View Article : Google Scholar : PubMed/NCBI
14	Belinsky SA: Silencing of genes by promoter hypermethylation: key event in rodent and human lung cancer. Carcinogenesis. 26:1481–1487. 2005. View Article : Google Scholar : PubMed/NCBI
15	Pfeifer GP and Rauch TA: DNA methylation patterns in lung carcinomas. Semin Cancer Biol. 19:181–187. 2009. View Article : Google Scholar : PubMed/NCBI
16	Fleischhacker M, Dietrich D, Liebenberg V, Field JK and Schmidt B: The role of DNA methylation as biomarkers in the clinical management of lung cancer. Expert Rev Respi Med. 7:363–383. 2013. View Article : Google Scholar
17	Charlet J, Schnekenburger M, Brown KW and Diederich M: DNA demethylation increases sensitivity of neuroblastoma cells to chemotherapeutic drugs. Biochem Pharmacol. 83:858–865. 2012. View Article : Google Scholar : PubMed/NCBI
18	Shang D, Liu Y, Matsui Y, et al: Demethylating agent 5-aza-2′-deoxycytidine enhances susceptibility of bladder transitional cell carcinoma to cisplatin. Urology. 71:1220–1225. 2008. View Article : Google Scholar : PubMed/NCBI
19	Han S, Sermba S, Abe T, Makino N, Furukawa T, Fukushige S, Takahashi H, Sakurada A, Sato M, Shiiba K, et al: Infrequent somatic mutations of the p73 gene in various human cancers. Eur J Surg Oncol. 25:194–198. 1999. View Article : Google Scholar : PubMed/NCBI
20	Yoshikawa H, Nagashima M, Khan MA, McMenamin MG, Hagiwara K and Harris CC: Mutational analysis of p73 and p53 in human cancer cell lines. Oncogene. 18:3415–3421. 1999. View Article : Google Scholar : PubMed/NCBI
21	Maas AM, Bretz AC, Mack E and Stiewe T: Targeting p73 in cancer. Cancer Lett. 332:229–236. 2013. View Article : Google Scholar : PubMed/NCBI
22	Zhao Y, Fei C, Zhang X, et al: Methylation of the p73 gene in patients with myelodysplastic syndromes: correlations with apoptosis and prognosis. Tumour Biol. 34:165–172. 2013. View Article : Google Scholar : PubMed/NCBI
23	Pei JH, Luo SQ, Zhong Y, Chen JH, Xiao HW and Hu WX: The association between non-Hodgkin lymphoma and methylation of p73. Tumour biol. 32:1133–1138. 2011. View Article : Google Scholar : PubMed/NCBI
24	Liu K, Zhan M and Zheng P: Loss of p73 expression in six non-small cell lung cancer cell lines is associated with 5′CpG island methylation. Exp Mol Pathol. 84:59–63. 2008. View Article : Google Scholar : PubMed/NCBI
25	Liu K, Zhuang X and Mai Z: p73 expression is associated with cellular chemosensitivity in human non-small cell lung cancer cell lines. Oncol Lett. 5:583–587. 2013.PubMed/NCBI
26	Kim DH, Nelson HH, Wiencke JK, et al: p16(INK4a) and histology-specific methylation of CpG islands by exposure to tobacco smoke in non-small cell lung cancer. Cancer Res. 61:3419–3424. 2001.PubMed/NCBI
27	Bearzatto A, Conte D, Frattini M, et al: p16(INK4A) hypermethylation detected by fluorescent methylation-specific PCR in plasmas from non-small cell lung cancer. Clin Cancer Res. 8:3782–3787. 2002.PubMed/NCBI
28	Shin KC, Lee KH, Lee CH, Shin IH, Suh HS and Jeon CH: MAGE A1-A6 RT-PCR and MAGE A3 and p16 methylation analysis in induced sputum from patients with lung cancer and non-malignant lung diseases. Oncol Rep. 27:911–916. 2012.PubMed/NCBI
29	Lou-Qian Z, Rong Y, Ming L, Xin Y, Feng J and Lin X: The prognostic value of epigenetic silencing of p16 gene in NSCLC patients: a systematic review and meta-analysis. PloS One. 8:e549702013. View Article : Google Scholar : PubMed/NCBI
30	Zinkel S, Gross A and Yang E: BCL2 family in DNA damage and cell cycle control. Cell Death Differ. 13:1351–1359. 2006. View Article : Google Scholar : PubMed/NCBI
31	Hervouet E, Vallette FM and Cartron PF: Impact of the DNA methyltransferases expression on the methylation status of apoptosis-associated genes in glioblastoma multiforme. Cell Death Dis. 1:e82010. View Article : Google Scholar : PubMed/NCBI